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Successful management of life-threatening 
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Jerry Goldstone, MD, Cleveland, Obio 
Acquired factor VIII inhibitor is increasingly recognized as a cause of major soft tissue hemorrhage. The laboratory 
diagnosis can be obscured by the synchronous presence of the lupus anticoagulant, an extremely rare occurrence that has 
been reported outside the vascular surgery literature. Vascular surgeons should be knowledgeable of factor VIII inhibitor 
and aware that it can present with other blood disorders, making the diagnosis more difficult and management more 
complex. This case report describes such a patient and reviews the current literature on this topic. (J Vasc Surg 2002;36: 
853-5.) 
The lupus anticoagulant is an antiphospholipid anti-
body that is associated with venous and arterial thrombotic 
complications. I-5 In contrast, acquired factor VIII defi-
ciency, caused by factor VIII inhibitor antibodies, com-
monly results in severe hemorrhagic complications. 6 -1o 
The simultaneous presence oflupus anticoagulant and fac-
tor VIII inhibitor is a rare occurrence that has been de-
scribed in association with hemophilia A, II myeloprolifer-
ative disorders,IO and connective tissue disorders. ll ,12 
Herein we present an unusual case of a previously undiag-
nosed patient v.ith synchronous lupus anticoagulant and 
factor VIII inhibitor who developed an upper extremity 
deep vein thrombosis and subsequently sustained a life-
threatening hemorrhage from a thigh hematoma. 
CASE REPORT 
A 64-year-old Afncan American woman wa, admitted to a 
nearby hospital with severe anemia (hematocrit, 17%) and a 2 -week 
history of left arm swelling and tmgling. Two units of packed red 
bloods cells (PRECs) were transfused. Esophagogastroduodenos-
copy and colonoscopy revealed only berugn-appearing colome 
polyps. A duplex scan of the left upper extremity was negative for 
deep venous thrombOSIS (DVT), and the patient was started on 
cefazolin for a presumptive diagnosis of celluhtis. The patient 
subsequently developed right upper arm swelling, guaiac-positive 
,tools, and mtermittent hypotensIOn, and she was transferred to 
UniverSity Hospitab of Cleveland for further evaluation. Her 
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medical history included chronic iron defiCiency anemia, hyperten-
Sion, chronic obstructive pulmonary disease, degenerative arthntis, 
and gastritis. Upon arnval at our institution, her medications 
included omeprazol, albuterol, ipratropium, cefazolin, lisinopril, 
doxazosin, hydrochlorothiazide, tramadol, aspirin, and ferrous 
,ulfate. Her surgical history was significant only for a hysterectomy 
years earlier. The family history was negative for thrombotic or 
bleedmg disorders. Admission vital signs included a temperature of 
37.10 C, pulse 101, blood pressure 120/40 mm Hg, and a respi-
ratory rate of 18. Physical examination was ,ignificant for marked 
right arm ,welling with 2 + pittmg edema from the shoulder to the 
fingertip, with accompanymg tenderness, and diminished shoulder 
strength and range of motion. The radial pube was diminished. 
The left upper extremity and both lower extremities appeared 
normal. Neurologic exammation showed no focal deficits. Initial 
laboratory studies were significant for a platelet count of 176 X 
109 /L, activated partial thromboplastin time (aPTT) of 77 sec-
onds, prothrombin time ofl4.2 seconds, and international normal 
ratIO (I~R) of 1.35. Lupus anticoagulant was diagnosed on the 
baSIS of mL'(ing studies that showed partial correction of the aPTT 
from 92 to 62 seconds and a prolonged dilute Russell viper venom 
time tl1at did not correct upon addinon of exogenous phospho-
lipid. Assays for antinuclear antibody and anti-DNA ann body were 
negative. Haptoglobm level was normal. Duplex scan of the right 
upper extremity revealed an occlusive thrombus in the midbrachial 
vein extending to the antecubital fo,sa. Abdominal and pelvic 
computed tomographic scans showed no retropentoneal hema-
toma. 
Because of the right arm DVT, the patient was started on 
enoxaparin and warfarin. However, this therapy wa, discontinued 
4 days later when the patient's INR became supratherapeunc 
(INR, 5.91, PT 62, PTT 148) and she developed a tense right 
thigh hematoma where she had had a femoral venou, line placed 7 
days earlier (sub,equently removed on day 3). The hematocrit fell 
from 27% to 17.6% and the vascular mrgery service was consulted 
to evaluate the tlligh hematoma, which had conunued to enlarge 
after removal of the venous line and was now accompanied by 
peroneal nerve palsy. After tlle patient's I~R was corrected to 1.5 
with vitamin K and fresh frozen plasma (FFP), she was taken to the 
853 
854 Brings et al 
operating room where a l;trge hematoma was evacuated from the 
adductor compartment. Although there was no evidence of active 
bleedmg, the patient continued to ooze copIou,ly from her right 
thigh wound. Overnight she received ~everal more units ofPRECs 
and FFl'. The next day her thIgh was re-explored, but again no 
active bleeding was found and the wound was now packed open. 
Because of her unstable hematoCrIt, a repeated abdominal com· 
puted tomogr.lphK scan wa~ obtained that again revealed no 
evidence of retroperitoneal bleeding. DespIte the~e aggre,sIve 
measures, the patient contInued to ooze from her thigh wound, 
and over the next 24 hours she received an addItIonal 8 unit~ of 
PRBC;,4 units ofFFP, and 10 packs ofplatdet,. 
Because of the patient's ongoing transfusion requirements and 
margmal hemodynamic stability, additional coagulatIOn srudies 
were urgently obtained, and tlle patient was found to have a high 
level off actor VIII mlllbItor (64 Bethesda units) associated \\1th no 
detectable factor VIII activity. Vitamm -K dependent coagulation 
factor, were also diminished (factor II 45%, tactor VII 21 %, and 
factor IX 20%), attributable to incomplete correction after W.lrlann 
therapy. Before the factor VIII inhibitor titer was obtamed, the 
patient was started on a continuous mhLsion of recombmant hu-
man factor VIII (5000 Uillt bolu; t(lllowed by 1000 units/h), 
although after 6 hours there appeared to be no re'ponse and the 
patient was started on factor VIII inhibitor hypassing activity 
[FEIBA (5 vials, 4360 unit~)]. The patient was also placed on 
immunosuppressive therapy consisting of oral dail~ cyclophmpha-
mide 100 mg and intravenous methylprednisolone 100 mg. She 
received six doses ofFEIBA (75 units/kg/8 h) over the next 36 
hours, and on thi; regimen the hematocrit stabilized at 37%. The 
PIT remained elevated at 55 second~. Becau~e of concern about 
the thrombogcnic potential of FEIBA, the patient was then 
switched to porcine factor VIII (initial dose 4950 unit; = 75 
uniTh/kg/8 h) with correction of the ele~ated PTT. A repeated 
factor VIII inhibitor level 1 week later remamed elevatcd at 76 
Bethe;d.1 umts. After 10 days with a stable hematocrit, the porcine 
factor VIII was discontInued and the PTT hegan to slowly nse 
without sequelae. The right thigh wound healed by ,econdary 
Intention with simple wound care. ApproXImately 6 weeks from 
her mitial hospitalization the patIent was transferred to a rehabIlt-
tation center on maintenance oral cyclophosphamIde, 50 mg daily, 
and oral prednisone, 30 mg daily, to be tapered ;lowly over 60 
days. 
DISCUSSION 
The lupus anticoagulant is an antiphospholipid immu-
noglobulin (Ig)G, IgA, or IgM antibody associated with an 
increased risk of venous or arterial thrombosis. Tn vitro, it 
causes an elevated PTT and was originally thought to lead 
to hemorrhagic complications; hmvever, it is now clear that 
this occurs only in the presence of other bleeding disorders 
or the "lupus anticoagulant-hypoprothrombinemia" syn-
drome.1,3.S Thus the term "anticoagulant" is a misnomer; 
the current preferred term is the antiphospholipid syn-
drome. 1,2,5 Lupus anticoagulant is estimated to occur in 
approximately 10% of vascular surgery patients and is asso-
Clated with a 27% incidence of early graft thrombosis in 
patients undergoing infrainguinal bypass. 3 Although lupus 
anticoagulant has been associated with the usc of many 
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dmgs,4 the mechanism by which it is acquired remains 
unclear, as is the pathway by which it leads to thrombo-
sis. l . s The presence oflupm anticoagulant should be sus-
pected in patients \vith an elevated PTT that does not 
correct when mixed with the plasma of a normal control. 
ConfirmatOlY tests for lupus anticoagulant include the Rus-
sell viper venom time, among others:")·5 If the presence of 
lupus anticoagulant is recognized preoperatively, then pre-
treatment with antiplatelet agents and anticoagulation arc 
recommended for vascular procedures. 3 
Factor VIII inhibitor is an acquired antibody, usually 
IgG, directed against factor VIII that is associated with an 
87% incidence of major hemorrhage with a 22% mortality. 
Although factor VIII inhibitor is rare, occurring in only 1 in 
5 million individuals per year, it is the most common 
neutralizing inhibitor against a specific clotting factor. 8 
Factor VIII inhibitors develop in 25% to 50% of patients 
with severe hemophilia A and in 5% to 10% of patients with 
mild-to-moderate hemophilia A during replacement with 
products containing factor VIII. In nonhemophihac pa-
tients, tactor VIII inhibitors usually develop in the absence 
of underlying disease, although it may accompany autoim-
mune disease, solid tumors, Iymphoproliferative disorders, 
and pregnancy. Lupus anticoagulant has been associated 
with the use of some medications, most notably the peni-
cillin antibiotics, phenytoin, phenylbutazones, and other 
antibiotics? Patients with f.lCtor VIII inhibitor usually 
present with unexplamed, occasionally life-threatening, 
hemorrhage.9 Hemorrhage usually occur~ in the soft tissues 
and may be brisk with associated nerve compression and 
compartment syndrome. Reported sites of hemorrhage 
include muscles and intracranial, retropharyngeal, and ret-
roperitoneal spaces. In contrast to congenital hemophilia, 
hemarthroses are rare. s As with lupus anticoagulant, the 
presence of factor VIII inhibitor should be suspected in the 
patient with a newly elevated aPTT. The PT is normal and 
the aPTT does not correct when patient plasma and normal 
plasma are mixed, although the aPTT may actually prolong 
further with prolonged incubation with normal plasma, as 
the inhibitor continues to inactivate factor VIII.8,9,16 Spe-
cific tactor VIII assays reveal decreased activity. Quantita-
tion of factor VIII inhibitor levels is performed by using the 
Bethesda unit assays and helps to guide therapy.S.16,17 
Only about 10% of patients with factor VIII inhibitor 
improve spontaneously, and intervention is almost always 
required. Although the management of factor VIII inhibi-
tor is not standardized, therapy usually consists of two 
phases: control of acute bleeding, if present, with transfu-
sion therapy; and suppression of inhibitor synthesis, usually 
WIth immunosuppressive therapy.8,17 Control of bleeding 
is usually accomplished with intravenous infusiom of re-
combinant human or porcine factor VIII; however, these 
may be immediately inactivated in patients with high inhib-
itor titers or cross-reactive inhibitors. In these patients, 
activated prothrombin complex concentrates (PCC) such 
as factor VIII inhibitor bypassing activity (FEIBA) or Au-
toplex T anti-inhibitor (Baxter Health Corp, Glendale, 
Calif) is indicated. These products are derived from pooled 
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human plasma and contain precursor and activated forms of 
factors II, VII, IX, and X. They aid coagulation by bypass-
ing the step in the intrinsic coagulation pathway normally 
mediated by factor VIII. The disadvantage of these prod-
ucts is the potential for thrombotic complications, as well as 
risk of viral transmission. Exchange transfusion and plasma-
pheresis have also been used successfully in patients with 
high inhibitor titers (>30 Bethesda uruts) who fail to 
respond to factor VIII replacement or PCc.8 Suppression 
of inhibitor synthesis often requires several weeks of treat-
ment and is usually accomplished with immunosuppressive 
therapy in the form of steroids with or without the addition 
of cyclophosphamide. Steroids alone induce complete re-
mission in approximately 25% of cases, whereas the addi-
tion of cyclophosphamide, azathioprine, immunoglobulin, 
or cyclosporin A may improve outcome.8 ,15,17 
The simultaneous presence of lupus anticoagulant and 
factor VIII inhibitor is exceedingly rare and to our knowl-
edge has not previollsly been reported in the vascular 
surgery literature, although it has been reported in a few 
patients with hemophilia A, myeloproliferative disorders, 
and connective tisslle disease.1l -14 Laboratory diagnosis is 
complicated by the fact that both entities present with an 
elevated PTT that does not correct with mixing studies, 
combining patient plasma with normal controls. The clin-
ical presentation may be helpful given that thrombosis 
usually occurs with lupus anticoagulant, whereas hemor-
rhage occurs with factor VIII inhibitor, although with 
either disorders the patient may remain asymptomatic. 
Only with a high index of suspicion and directed assays such 
as the Russell viper venom time, factor VIII assay, and the 
Bethesda assay for quantitation of factor VIII inhibitor can 
the correct diagnosis be confirmed. Unfortunately these 
tests are usually not readily available and initial treatment 
may of necessity be empirical. The management of hemor-
rhage caused by factor VIII inhibitor can be complicated by 
thrombosis. We were particularly concerned with this pos-
sibility in our patient, who we felt to be at high risk for 
thrombotic complications because of her lupus anticoagu-
lant and recent DVT. 
Although aside from this single patient we have had no 
other experience with the management of patients with 
known factor VIII inhibitor who require surgery, we would 
make the following recommendations regarding this situa-
tion: (1) postpone elective surgery and treat with immuno-
therapy until the factor VIII inhibitor reaches undetectable 
levels and (2) obtain consultation with a hematologist 
knowledgeable in the management of coagulopathies. 
CONCLUSIONS 
Factor VIII inhibitor is a rare entity that often presents 
with life-threatening so£,!: tissue hemorrhage and is associ-
Brings et al 855 
ated with a high mortality rate. It should be suspected in 
patients with unexplained soft tissue hemorrhage in the 
presence of an elevated PTT. Management is complex and 
hematologic consultation is recommended. The simulta-
neous. occurrence of lupus anticoagulant and factor VIII 
inhibitor is even rarer and presents additional challenges in 
diagnosis and management. 
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